Live Breaking News & Updates on Haematological oncology

Stay updated with breaking news from Haematological oncology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Onco-hematology Molecular Testing Market 2024-2031 | Exclusive Study Report By Top Research Firm

Onco-hematology Molecular Testing Market 2024-2031 | Exclusive Study Report By Top Research Firm
whatech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from whatech.com Daily Mail and Mail on Sunday newspapers.

Argentina , Mexico , United-states , South-africa , South-korea , Germany , United-kingdom , France , Brazil , Canada , American , Canadians

CellCentric's inobrodib exhibits a novel mechanism of action with potential to treat a number of haematological malignancies: new data published in Cancer Cell

Inobrodib exhibits encouraging preclinical and early-phase clinical activity through disrupting the action of p300/CBP at regulatory elements controlling key cancer genes.Inobrodib is the first in a new class of drug with promise in relapsed refractory multiple myeloma and other haematological malignancies.Patients. ....

San-diego , California , United-states , Cambridge , Cambridgeshire , United-kingdom , Arizona , Manchester , American , Emma-searle , Leif-bergsagel , Tim-somervaille

Clinical trial gives terminal cancer patient new lease of life

Clinical trial gives terminal cancer patient new lease of life A retired primary school teacher with a matter of months to live is now enjoying life thanks to a new blood cancer drug she is taking as part of a clinical trial at The Christie NHS Foundation Trust in Manchester. Six years ago Chris (Christine) Ren. ....

United-kingdom , Wirral , Manchester , Merseyside , United-kingdom-general , Emma-searle , Chris-christine-rennie , Chris-rennie , Tim-somervaille , Cancer-research-united-kingdom-manchester-institute , Christie , University-of-manchester

CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma

CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Arizona , United-states , Cambridge , Cambridgeshire , United-kingdom , Manchester , American , Prnewswire-cellcentric , Tim-somervaille , Paul-richardson , Azim-surani , Leif-bergsagel

CellCentric to present inobrodib Phase I multiple myeloma efficacy and safety data at the American Society of Haematology

CellCentric to present inobrodib Phase I multiple myeloma efficacy and safety data at the American Society of Haematology
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Cambridge , Cambridgeshire , United-kingdom , United-states , Manchester , American , Andrew-hughes , Prnewswire-cellcentric , Tim-somervaille , Azim-surani , University-of-cambridge , Takeda-pharmaceuticals